One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419…
We are excited to welcome Onena Medicines as our newest portfolio company! Onena Medicines is a Swiss-Spanish biotech company emerging from the Chan Zuckerberg Biohub…
Engimmune is a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, founded in August 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof Sai Reddy and Dr…
Cimeio therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research by Professor Lukas Jeker–co-founder…
2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…
We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…
We are excited to welcome Stromal Therapeutics as our newest portfolio company! Basel, Switzerland., 28 January 2022 — Stromal Therapeutics is emerging from one of…
FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG…
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…